Erlotinib Completed Phase 2 Trials for Glioblastomas / Gliosarcoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00525525Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
NCT00337883A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
NCT00672243Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
NCT00671970Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)